On the final day of the 2023 World Conference on Lung Cancer (WCLC) , Oncology Frontier had the privilege of interviewing Dr. Wu Yilong from Guangdong Provincial People’s Hospital, Dr. Cheng Ying from Jilin Cancer Hospital, and Dr. Han Baohui from Shanghai Chest Hospital. These three experts participated in a dialogue and discussion regarding hot topics at the conference and significant clinical research. Here present the highlights of their on-site discussions.
Experiencing the 2023 World Conference on Lung Cancer
For the first time in three years, Chinese experts were able to participated in the WCLC conference in person, following the end of the impact of the COVID-19 pandemic , engaging in face-to-face discussions with international scholars. Dr. Wu Yilong, Dr. Cheng Ying, and Dr. Han Baohui shared their experiences of attending the conference in Singapore.
Important Research on Small Cell Lung Cancer (SCLC) at WCLC 2023: Chinese Scholars’ Investigation into Anti-Angiogenic Drug Combination Therapy
Dr. Cheng Ying delivered two research presentations on Chinese SCLC at the first oral session of WCLC 2023. The first was a randomized double-blind Phase III study evaluating the efficacy and safety of the four-drug combination of PD-L1 antibody TQB2450 (Benmelstobart), anlotinib, and chemotherapy as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) (Abstract OA01.03). Dr. Cheng Ying explained the design and key results of this study during the interview. The second study was the Phase III RATIONALE-312 trial of chemotherapy ± toripalimab as first-line treatment for extensive-stage SCLC (Abstract OA01.06). Subsequently, Dr. Han Baohui introduced her team’s exploration of anlotinib-based combination therapy for small cell lung cancer and non-small cell lung cancer. Dr. Wu Yilong also provided his assessment of the value of this combination treatment strategy.
TQB2450 Combined with Anlotinib + Chemotherapy as First-Line Treatment for ES-SCLC
Progress and the promise of Antibody-Drug Conjugate (ADC) at WCLC 2023
ADCs have emerged as one of the research hotspots in recent years. Dr. Cheng Ying introduced the current status of ADC development in China and the value of ADCs in lung cancer treatment.
She also shared the subgroup analysis results of the Phase I/II study of the B7H3 ADC I-DXd (DS-7300) in the treatment of refractory SCLC patients (Abstract OA05.05). Dr. Han Baohui delved into the mechanism of ADCs, the toxicity characteristics, and future development directions. Dr. Wu Yilong analyzed the trends in ADC development and expressed his high expectations for innovative breakthroughs from Chinese researchers and pharmaceutical companies.
Phase I/II Study of I-DXd in the Treatment of Refractory SCLC Patients
Expert Profiles
Dr. Wu Yilong
Lifetime Director, Guangdong Provincial People’s Hospital (GGH)
Honorary Director, Guangdong Lung Cancer Institute (GLCI)
Dr. Cheng Ying
Full Professor, Doctoral Supervisor, Postdoctoral Supervisor
Recipient of the State Council Special Allowance, Outstanding Young and Middle-aged Experts with Outstanding Contributions to Health by the Ministry of Health
Director of Jilin Province Cancer Center
Director of Jilin Province Lung Cancer Diagnosis and Treatment Center
Dr. Han Baohui
Leading Talent of Shanghai Municipality, Distinguished Discipline Leader
Executive Dean of the Chinese Lung Cancer Institute
